X4 Pharmaceuticals Q2 2026: EU Nod for XOLREMDI and Cash Runway Through 2029
XFOR has more than doubled off its 52-week low of $1.35.
Summary
X4 Pharmaceuticals posted Q2 2026 results featuring EU approval for XOLREMDI, revenue of $8.8M, and a cash runway extended to 2029, removing near-term going concern risk.
Updates
· GlobeNewswire — Phase 3 4WARD trial operations overhauled with a top CRO and over 110 sites activated; FDA meeting and enrollment completion update expected by end of Q3. EU marketing authorization transferred to Norgine, unlocking up to €221M in milestones plus double-digit royalties.
Key Events · Earnings and Guidance · XFOR
-
EU Approval for XOLREMDI
Marketing authorization from the European Commission for XOLREMDI (mavorixafor) in WHIM syndrome triggered a €5.0M milestone payment from partner Norgine and opens the EU market.
-
Revenue Surge to $8.8M
Total revenue reached $8.8M in Q2 2026, up from $2.0M in Q2 2025, driven by $5.5M in license revenue from the Norgine milestone and $2.4M in U.S. product sales.
-
Cash Runway Extended to 2029
Cash, equivalents, and marketable securities stood at $208M as of June 30, 2026, funding operations into 2029 and removing the near-term going concern risk.
-
New $75M ATM Program Established
On May 6, 2026, the company entered into an Open Market Sale Agreement to sell up to $75M of common stock; as of August 6, 2026, no shares have been sold under the program.
Analysis · XFOR · Life Sciences
A pivotal quarter for X4 Pharmaceuticals. The European Commission granted marketing authorization for XOLREMDI in WHIM syndrome, unlocking a new revenue stream through partner Norgine. Q2 revenue surged to $8.8M from $2.0M a year ago, fueled by a $5.5M regulatory milestone and growing U.S. product sales. With $208M in cash, the runway now extends into 2029, eliminating the near-term going concern risk that had weighed on the stock. A new $75M ATM program adds further financial flexibility, though no shares have been sold yet. Restructuring savings helped narrow the net loss to $16.2M. This quarter marks a shift from survival to execution.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.8% of the 988 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XFOR was trading at $4.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $393.3M. The 52-week trading range was $1.35 to $4.83. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.